1 week ago
HCW Biologics (HCWB) Stock: Licensing Deal Fuels Q1 Revenue Surge Amid Nasdaq Compliance Battle
HCW Biologics (HCWB) stock posts $6.54M Q1 revenue and $3.47M profit from Trimmune deal, but faces Nasdaq delisting hearing over share price compliance.
The post HCW Biologics (HCWB) Stock: Licensing Deal Fuels Q1 Revenue Surge Amid Nasdaq Compliance Battle appeared first on Blockonomi.
Source: Blockonomi →Related News
- 16 hours ago
Hewlett Packard Enterprise (HPE) Stock Soars to Record Peak as Elliott Expands P...
- 16 hours ago
Norwegian Cruise Line (NCLH) Stock Plummets 9.5% — Company Insiders Buy Big
- 16 hours ago
Dell (DELL) Stock Rockets 16% to All-Time Peak Ahead of May 28 Earnings
- 16 hours ago
BlackBerry (BB) Stock Surges 19% to New 52-Week Peak on Bullish Outlook
- 16 hours ago
Navitas Semiconductor (NVTS) Stock Soars 20% as AI Power Shift Fuels Rally